Q-omics provides the consensus-scored ZDHHC21 profile across patient tissues and cancer cell-line models. ZDHHC21 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZDHHC21 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, ZDHHC21 RNA expression shows 21,121 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUSC, and UVM as cancer lineages where ZDHHC21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC21 survival associations across molecular data types. ZDHHC21 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC21 RNA expression–survival associations across cancer types. High ZDHHC21 expression shows unfavorable associations in UVM, but favorable associations in KIRC, BLCA, SKCM, BRCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZDHHC21 RNA expression.
This table summarizes ZDHHC21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZDHHC21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC21 shows lower tumor expression in LUSC, KIRC, COAD and KIRP and higher tumor expression in CHOL and LIHC. The LUSC box plot shows higher ZDHHC21 RNA expression in normal versus tumor tissue (log2 FC = −0.677, t-test p < 0.001).
This table shows molecular features associated with ZDHHC21 in patient tissues and cancer cell lines. In patient samples, ZDHHC21 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_SCLC.
